Notwithstanding, in patients without severe iron deficiency and active inflammation at the time of evaluation, hepcidin was associated with lower MCV, i.e. with iron-restricted erythropoiesis, suggesting that it negatively influences iron availability to the erythron, and that it represents a potential therapeutic target to improve anemia management. Here, HAMP is linked to Iron deficiency anemia.